Meeting
2022 ASCO Annual Meeting
Clinical impact of MAPK pathway alterations in advanced biliary tract cancer (BTC): SCRUM-Japan GOZILA and COLOMATE international collaboration.
Authors
Hideaki Takahashi
Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
Hideaki Takahashi , Bennett Adam Caughey , Kumiko Umemoto , Michelle Green , Michael Datto , Makoto Ueno , Daniel Walden , Taito Esaki , Thomas Oliver , Yoshito Komatsu , Nobumasa Mizuno , Eiji Oki , Hiroya Taniguchi , Hideaki Bando , Chigusa Morizane , Takayuki Yoshino , John H Strickler , Masafumi Ikeda , Tanios S. Bekaii-Saab , Yoshiaki Nakamura
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4086)
DOI
10.1200/JCO.2022.40.16_suppl.4086
Abstract #
4086
Poster Bd #
73
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
First Author: Taro Shibuki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 2, open-label, safety and efficacy study of telotristat ethyl plus first-line chemotherapy in patients with advanced biliary tract cancer.
First Author: Richard D. Kim
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Comprehensive clinico-molecular profile and efficacy of anti-HER2 therapy for HER2-amplified biliary tract cancer.
First Author: Kanae Inoue
Poster
2023 ASCO Annual Meeting
Sintilimab plus gemcitabine and cisplatin as a first-line treatment for patients with advanced biliary tract cancer: A biomolecular exploratory, phase II clinical trial.
First Author: Zhen-gang Yuan